Scemblix generics — when can they launch?
Scemblix (ASCIMINIB HYDROCHLORIDE) · Novartis · 12 active US patents · 0 expired
Where Scemblix sits in the generic timeline
Long-dated protection: earliest active US patent for Scemblix extends to 2035 (~9 years out). Generic competition is at least 4 years away. Lifecycle moves (new formulations, label extensions, combination filings) typically execute 18-36 months ahead of cliff.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 6 patents
- Formulation — 3 patents
- Composition of Matter — 3 patents
FDA U-codes carved out by Scemblix patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-1374 | (no description) |
Sample patent estate
Showing 6 of 12 active US patents. View full estate on the Scemblix drug page →
-
This patent protects compounds that inhibit the activity of BCR-ABL1 and its mutants, which are used in the treatment of cancers.USPTO title: Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
-
This patent protects compounds that inhibit the activity of BCR-ABL1 and its mutants, which are used in the treatment of cancers.USPTO title: Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
-
This patent protects compounds that inhibit the activity of BCR-ABL1 and its mutants, which are used in the treatment of cancers.USPTO title: Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
-
This patent protects specific crystalline forms of the compound N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide.USPTO title: Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
-
This patent protects specific crystalline forms of the molecule N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide.USPTO title: Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
-
This patent protects specific crystalline forms of the molecule N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide.USPTO title: Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
Sources
- FDA Orange Book — patents listed against Scemblix (NDA filed 2021)
- Scemblix drug profile — full patent estate, indications, clinical trials, pricing
- Novartis patent portfolio
- Patent cliff 2035 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Scemblix — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →